Biofrontera AG
B8F.DE
Get informed when a big investor buys or sells
+ FollowMarket Cap$434.14M
Close$
$-1.41
120.8% downside
Current Fair Value
120.8% downsideOvervalued by 120.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $434.14 Million |
|---|---|
| Enterprise Value | $436.99 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.01 |
| Beta | 0.64 |
| Outstanding Shares | 63,807,058 |
Return
| Return on Equity | -106.87% |
|---|---|
| Return on Assets | -26.45% |
| Return on Invested Capital | -50.93% |
Valuation & Multiples
| P/E Ratio | -1.62 |
|---|---|
| PEG | 1.82 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 9.46 |
| Enterprise Value to EBIT | -63.45 |
| Enterprise Value to Net Income | -69 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 1.26 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Biofrontera Inc
82 employees
CEO: Hermann Lübbert Biofrontera AG, a biopharmaceutical company, engages in the research, development, and distribution of dermatological products in Germany, Spain, the United Kingdom, rest of Europe, the United States, and internationally. The company off...